After CAR-T Transfer, Gilead Sets Cell Therapy as Key Biz Pillar for Growth in Japan

Gilead Japan President Kennet Brysting (right) and Development Head Masa Omote After taking over CAR T-cell therapy Yescarta (axicabtagene ciloleucel) from Daiichi Sankyo, the Japan arm of Gilead Sciences is poised to turn the cell therapy business into a key...read more